NCT05786924 2025-11-20Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesServierPhase 1/2 Recruiting554 enrolled
NCT02393248 2023-01-06Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)Incyte CorporationPhase 1/2 Terminated201 enrolled 71 charts